Cargando…

Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment

PURPOSE: To explore the factors that influence the short-term clinical outcome after the first (131)I treatment of papillary thyroid micro carcinoma (PTMC). PATIENTS AND METHODS: From October 2015 to June 2018, patients who were diagnosed with PTMC with lymph node metastasis were analyzed retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Jingjia, Yun, Canhua, Zhu, Xiaolu, Li, Xiao, Sun, Yaru, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214364/ https://www.ncbi.nlm.nih.gov/pubmed/34163244 http://dx.doi.org/10.2147/CMAR.S308012

Ejemplares similares

Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
por: Cao, Jingjia, et al.
Publicado: (2022)

Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy
por: Yun, Canhua, et al.
Publicado: (2021)

I(131) Accumulation in Hydrocele in the Setting of Metastatic Papillary Carcinoma Thyroid
por: Seetharam, SJ, et al.
Publicado: (2022)

Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma
por: Zheng, Lei, et al.
Publicado: (2022)

Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First (131)I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma
por: Shangguan, Linjue, et al.
Publicado: (2021)

Analysis of factors influencing the clinical outcome after surgery and (131)I therapy in patients with moderate-risk thyroid papillary carcinoma
por: Li, Yixuan, et al.
Publicado: (2022)

Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
por: Okamoto, Shozo, et al.
Publicado: (2013)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Analysis of the incidence and influencing factors of hyponatremia before (131)I treatment of differentiated thyroid carcinoma
por: Cao, Jing-Jia, et al.
Publicado: (2021)

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
por: Xiao, Juan, et al.
Publicado: (2021)

Hiatal hernia uptake of iodine-131 mimicking mediastinal metastasis of papillary thyroid carcinoma
por: Haghighatafshar, Mahdi, et al.
Publicado: (2015)

AN UNUSUAL CASE OF PAPILLARY THYROID CARCINOMA IODINE-131 AVID METASTASIS TO THE ADRENAL GLAND
por: Blažeković, Ivan, et al.
Publicado: (2018)

Changes of Regulatory T and B Cells in Patients with Papillary Thyroid Carcinoma after (131)I Radioablation: A Preliminary Study
por: Jiang, Lei, et al.
Publicado: (2013)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

Is (131)I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
por: Rosario, Pedro Weslley, et al.
Publicado: (2016)

The Molecular Effect of Diagnostic Absorbed Doses from (131)I on Papillary Thyroid Cancer Cells In Vitro
por: Stasiołek, Mariusz, et al.
Publicado: (2017)

A Comparison of Clinicopathological Characteristics and Short-Term Outcome of Papillary Thyroid Carcinoma with Tall Cell Histology and Classic Papillary Thyroid Carcinoma: A Single-Institution Experience
por: Sampathkumar, Geethalakshmi, et al.
Publicado: (2018)

Cervical lymph node metastasis prediction of postoperative papillary thyroid carcinoma before (131)I therapy based on clinical and ultrasound characteristics
por: Yu, Fei, et al.
Publicado: (2023)

Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine
por: Yun, Canhua, et al.
Publicado: (2021)

lncRNA CASC2 Enhances (131)I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155
por: Tao, Ling, et al.
Publicado: (2020)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2015)

Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma
por: Huang, Hui, et al.
Publicado: (2017)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-(131)I-avid lung metastases
por: Song*, Hong-Jun, et al.
Publicado: (2013)

False-positive I-131 Uptakes at Pulmonary Wedge-resection Site and Soft Tissue Lateral to the Femoral Heads in a Patient with Papillary Thyroid Carcinoma
por: Yazıcı, Bülent, et al.
Publicado: (2019)

A case of the accumulation of 131-iodine in the mammary gland after remnant ablation for papillary thyroid carcinoma on lactating period
por: Murayama, Daisuke, et al.
Publicado: (2021)

Renal Metastasis and Dual ((18)F-Fluorodeoxyglucose and (131)I) Avid Skeletal Metastasis in a Patient with Papillary Thyroid Cancer
por: Kulkarni, Prashanth, et al.
Publicado: (2017)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis
por: Lin, Shang, et al.
Publicado: (2021)

Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid. Case report
por: Thom, Anneliese Rosmarie Gertrud Fischer, et al.
Publicado: (2014)

LncRNA-SLC6A9-5:2: a potent sensitizer in (131)I-resistant papillary thyroid carcinoma with PARP-1 induction
por: Xiang, Cheng, et al.
Publicado: (2017)

A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma
por: Hao, Jie, et al.
Publicado: (2023)

Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2018)

A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma
por: liu, Yan, et al.
Publicado: (2021)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Differential Expression Profiling and Functional Analysis of microRNAs through Stage I-III Papillary Thyroid Carcinoma
por: Zhang, Jing, et al.
Publicado: (2013)

Variants in microRNA genes in familial papillary thyroid carcinoma
por: Tomsic, Jerneja, et al.
Publicado: (2016)

Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling
por: Galuppini, Francesca, et al.
Publicado: (2022)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n4sslbbj7g2i3up826mt0vq1pb